Gilead Sciences
GILD | NASDAQ
$167.58
-$0.50 (-0.30%)
At close: Nov 16, 2026, 4:00 PM ET
$169.14
+$1.56 (+0.93%)
After-hours:
Nov 16, 2026, 7:46 PM ET
Gilead Sciences Company Profile
Company profile explainedCompany Profile
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Key Executives
| Name | Position |
|---|---|
| Daniel O'Day | Chairman & Chief Executive Officer |
| Andrew D. Dickinson | Executive VP & CFO |
| Dietmar Berger | Chief Medical Officer |
| Erin Burkhart | Senior VP, Controller & Chief Accounting Officer |
| Flavius Martin | Executive Vice President of Research |
| Jacquie Ross | Senior Vice President of Treasury and Investor Relations |
| Janet Dorling | Senior Vice President of Intercontinental Region & Global Patient Solutions |
| Johanna Mercier | Chief Commercial & Corporate Affairs Officer |
| Jyoti K. Mehra | Executive Vice President of Human Resources |
| Keeley Wettan | Executive VP, General Counsel of Legal & Compliance and Secretary |
| Linda Slanec Higgins | Senior Vice President of Research, Innovation & Portfolio |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 16, 2026 | 4 | Filing |
| Oct 16, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 11, 2026 | 4 | Filing |
| Sep 11, 2026 | 4 | Filing |
Gilead Sciences
| Country | United States |
| IPO Date | Jan 22, 1992 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 17,000 |
| CEO | Daniel O'Day |
Contact Details
333 Lakeside Drive Foster City,
California 94404 United States
Stock Details
| Ticker Symbol | GILD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000882095 |
| CUSIP Number | 375558103 |
| ISIN Number | US3755581036 |
| SIC Code | 2836 |
Recent News
- 10 hours ago / businesswire.comGilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
- 1 day ago / 247wallst.comGilead Beat the S&P 500 by More Than 25 Points in the Past Year, but $1,000 From a Decade Ago Is Still Worth Less Than $3,500
- 4 days ago / zacks.comCan Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
- 6 days ago / seekingalpha.comGilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
- 6 days ago / marketbeat.comGilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch
- 6 days ago / fool.comGilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
- 10 days ago / 247wallst.comGilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe?
- 12 days ago / fool.comGilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.
- 13 days ago / zacks.comGilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
- 15 days ago / businesswire.comGilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
Add to Watchlist
Select watchlists to add or remove GILD